|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 777 6th Street NW |
Address2 | 8th FL |
| City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 400976792-1305
|
||||||||
|
6. House ID# 421310129
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Zachary Williams |
Date | 10/16/2021 10:28:21 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Edward |
Reno |
III |
|
|
Derrick |
White |
|
|
|
Jeff |
Sadosky |
|
|
|
Jay |
Driscoll |
|
|
|
Zachary |
Williams |
|
|
|
Ryan |
Welch |
|
|
|
Libby |
Greer |
|
|
|
Kristina |
Dunklin |
|
|
|
Francesca |
McCrary |
|
|
|
Cindy |
Brown |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Edward |
Reno |
III |
|
|
Derrick |
White |
|
|
|
Jeff |
Sadosky |
|
|
|
Jay |
Driscoll |
|
|
|
Zachary |
Williams |
|
|
|
Ryan |
Welch |
|
|
|
Libby |
Greer |
|
|
|
Kristina |
Dunklin |
|
|
|
Francesca |
McCrary |
|
|
|
Cindy |
Brown |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |